Royce & Associates LP Acquires 248,081 Shares of Envista Holdings Co. (NYSE:NVST)

Royce & Associates LP boosted its stake in Envista Holdings Co. (NYSE:NVST) by 88.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 526,985 shares of the company’s stock after acquiring an additional 248,081 shares during the period. Royce & Associates LP owned 0.31% of Envista worth $10,166,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Natixis Advisors LLC boosted its stake in shares of Envista by 1.8% during the 4th quarter. Natixis Advisors LLC now owns 106,652 shares of the company’s stock valued at $2,057,000 after purchasing an additional 1,845 shares in the last quarter. Swiss National Bank boosted its position in Envista by 0.8% during the 4th quarter. Swiss National Bank now owns 338,200 shares of the company’s stock valued at $6,524,000 after acquiring an additional 2,800 shares in the last quarter. Pzena Investment Management LLC bought a new stake in Envista during the 4th quarter valued at approximately $16,979,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Envista by 17.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,057 shares of the company’s stock worth $811,000 after acquiring an additional 6,320 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Envista in the 4th quarter worth approximately $10,808,000.

Envista Stock Up 3.0 %

Envista stock opened at $17.16 on Tuesday. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -2.64, a PEG ratio of 1.27 and a beta of 1.33. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. Envista Holdings Co. has a 12 month low of $15.15 and a 12 month high of $23.00. The stock has a fifty day simple moving average of $19.94 and a two-hundred day simple moving average of $19.64.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities analysts predict that Envista Holdings Co. will post 1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NVST. JPMorgan Chase & Co. dropped their price target on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. New Street Research set a $19.00 target price on shares of Envista in a research report on Thursday, March 6th. Jefferies Financial Group increased their price target on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Morgan Stanley dropped their price objective on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. Finally, UBS Group decreased their target price on shares of Envista from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Monday, March 10th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $20.18.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.